title: [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
abstract: The 2012 World Health Assembly Global Vaccine Action Plan called for global access to new vaccines within 5 years of licensure. Current approaches have proven insufficient to achieve sustainable vaccine pricing within such a timeline. Paralleling the successful strategy of generic competition to bring down drug prices, a clear consensus is emerging that market entry of multiple suppliers is a critical factor in expeditiously bringing down prices of new vaccines. In this context, key target objectives for improving access to new vaccines include overcoming intellectual property obstacles, streamlining regulatory pathways for biosimilar vaccines, and reducing market entry timelines for developing-country vaccine manufacturers by transfer of technology and know-how. I propose an intellectual property, technology, and know-how bank as a new approach to facilitate widespread access to new vaccines in low- and middle-income countries by efficient transfer of patented vaccine technologies to multiple developing-country vaccine manufacturers.
authors: Departamento de Medicina de Urgencias, Universidad de California en Los Ángeles, Los Ángeles, California, Estados Unidos de América.
authors: Sara Eve
authors: SE
authors: Crager
mesh_terms: D059451:Biosimilar Pharmaceuticals / Q000191:economics / Q000600:supply & distribution; D003363:Cost Control; D019992:Databases as Topic; D003906:Developing Countries; D016527:Drug Costs; D004345:Drug Industry; D006297:Health Services Accessibility; D006801:Humans; D018973:Intellectual Property; D007880:Legislation, Drug; D010330:Patents as Topic; D015397:Program Evaluation; D018581:Technology Transfer; D014612:Vaccines / Q000191:economics / Q000600:supply & distribution*; D014944:World Health Organization
chemical_list: D059451:Biosimilar Pharmaceuticals; D014612:Vaccines